Previous 10 | Next 10 |
Under accelerated review status, the FDA approves Epizyme's ( EPZM +4.5% ) Tazverik (tazemetostat) for the treatment of adult patients with relapsed/refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have receive...
TAZVERIK Now Approved for Second Indication Commercial Organization Fully Prepared to Support Successful Launch in Follicular Lymphoma Company to Host Conference Call Today at 2:30 p.m. ET Epizyme, Inc . (Nasdaq:EPZM), a fully integrated, commercial-stage biopharmaceut...
June holds plenty of catalysts for biotechnology stocks -- especially those specializing in cancer treatments. Investors with extra cash on the sidelines may be able to capture some exciting cancer stocks at attractive prices. These small-cap biotechnology stocks when held in the long term can...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
It should first be noted we did not consult with Epizyme, Inc. in the preparation of this article. Our analysis concludes Epizyme, Inc.'s (EPZM) is an incredible company and EPZM's product Tazverik could have a bright future treating those who suffer from Follicular Lymphoma. EPZM's Tazverik...
Epizyme, Inc . (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today announced that multiple abstracts have been accepted for poster presentations during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scient...
Image source: The Motley Fool. Epizyme Inc (NASDAQ: EPZM) Q1 2020 Earnings Call May 4, 2020 , 9:00 a.m. ET Operator Continue reading
Epizyme, Inc. (EPZM) Q1 2020 Earnings Conference Call May 04, 2020 9:00 AM ET Company Participants Alicia Davis - Investor Relations Officer Rob Bazemore - Chief Executive Officer Matt Ros - Chief Strategy & Business Officer Shefali Agarwal - Chief Medical Officer Paolo T...
The following slide deck was published by Epizyme, Inc. in conjunction with their 2020 Q1 earnings Read more ...
Epizyme ( EPZM ) Q1 results : More news on: Epizyme, Inc., Healthcare stocks news, Earnings news and commentary, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
TAZVERIK® (tazemetostat) Net Product Revenue of $11.0 Million for 2Q 2022; Total End User Demand Grew 17% vs. 1Q 2022 First Patient Dosed in the SET-101 Phase 1/1b Study of EZM0414, the Company’s Novel, First-in-Class, Oral SETD2 Inhibitor Merger with I...
The biotech investment sector has always been its own market, very distinct from other sectors. So it was no surprise that when most sectors turned slowly upward after the pandemic-inspired crash, Biotech (XBI) rose 164%, exceeding the overall market (SPY) performance by triple digits. Then, a...
Shares of the commercial-stage cancer company Epizyme (NASDAQ: EPZM) are soaring today. Specifically, the drugmaker's stock is up by a handsome 58% as of 10:50 a.m. ET Monday. Epizyme's shares are racing higher today in response to a buyout agreement with French biopharma Ipse...